keep away from direct sunlight,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Spliceostatin A 是 抗癌剂和剪接抑制剂,抑制剪接体剪接机制,抑制有丝分裂克隆扩增和脂肪生成。Spliceostatin A 诱导细胞周期停滞在 G1 和 G2/M 期,诱导细胞凋亡。
产品描述 | Spliceostatin A is an anticancer agent and splicing inhibitor that inhibits the splicing mechanism of the spliceosome and inhibits mitotic clonal expansion and adipogenesis.Spliceostatin A induces cell cycle arrest in the G1 and G2/M phases, and induces apoptosis. |
靶点活性 | SF3B1 (WT):5.5 nM, SF3B1 (mutant):4.9 nM |
体外活性 | Spliceostatin A(0、2.5 nM、5 nM、10 nM和20 nM;0、6小时、12小时和24小时)能增加慢性淋巴细胞白血病细胞的凋亡[1]。 |
体内活性 | BTA-EG4 (30 mg/kg; injections; daily; 2 weeks) improved dendritic spine density and cognitive function of 3xTg AD mice in an age-dependent manner. BTA-EG4 injected 3xTg AD mice at 6-10 months of age showed improved learning and memory; however, only minimal improvement was observed at 13-16 months of age. This behavioral improvement corresponds to a decrease in soluble Aβ 40 levels. These findings suggest that BTA-EG4 may be beneficial in ameliorating the synaptic loss seen in early AD.[2] |
分子量 | 521.643 |
分子式 | C28H43NO8 |
CAS No. | 391611-36-2 |
keep away from direct sunlight,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Spliceostatin A 391611-36-2 Apoptosis Inhibitor inhibitor inhibit